Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population

World Journal of Gastroenterology

Volumn 14, Issue 14, 2008, Pages 2218-2221

  Zuberi, Bader Faiyaz ^a   Zuberi, Faisal Faiyaz ^b   Memon, Sajjad Ali ^a   Qureshi, Muhammad Hafeez ^a   Ali, Sheikh Zafar ^a   Afsar, Salahuddin ^a  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b Nehal Hospital   (Pakistan)

Author keywords

Chronic hepatitis; Hepatitis C; Rapid virological responders; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA2A INTERFERON; PROTHROMBIN; RIBAVIRIN; VIRUS RNA; INTERFERON;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PAKISTAN; PROTHROMBIN TIME; QUALITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RNA ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; VIROLOGY; CLINICAL TRIAL; GENETICS; INTERVENTION STUDY; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME;

ADULT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERVENTION STUDIES; MALE; PAKISTAN; RNA, VIRAL; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 49249084393     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2218     Document Type: Article

References (22)

1. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-29
2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441
3. Ahmad N, Asgher M, Shafique M, Qureshi JA. An evidence of high prevalence of Hepatitis C virus in Faisalabad, Pakistan. Saudi Med J 2007; 28: 390-395
4. Moatter T, Hussainy AS, Hamid S, Alunad Z, Siddiqui S. Comparative analysis of viral titers and histologic features of Pakistani patients infected with hepatitis C virus type 3. Int J Infect Dis 2002; 6: 272-276
5. Shah HA, Jafri W, Malik I, Prescott L, Simmonds P. Hepatitis C virus (HCV) genotypes and chronic liver disease in Pakistan. J Gastroenterol Hepatol 1997; 12: 758-761
6. Ahmad M, Bukhari A, Ghanni MHU, Khan A, Malik JI, Shah AH. Prevalence of hepatitis C virus and its serotypes in Bahawalpur Division. Biomedica 2003; 19: 18-22
7. Crespo M, Esteban JI, Ribera E, Falco V, Sauledi S, Buti M, Esteban R, Guardia J, Ocana I, Pahissa A. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/ HIV co-infected patients. AIDS 2007; 21: 477-481
8. Nakamura J, Kobayashi K, Toyabe SI, Aoyagi Y, Akazawa K. The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. Eur J Gastroenterol Hepatol 2007; 19: 733-739
9. Dalgard O, Mangia A. Short-Term Therapy for Patients with Hepatitis C Virus Genotype 2 or 3 Infection. Drugs 2006; 66: 1807-1815
10. Sample Size Determination in Health Studies. [Computer Programme]. Ver 2.0 Geneva: World Health Organization, 1998
11. Statistical Package for Social Sciences (SPSS). [Computer program]. Chicago: SPSS Inc., 2006
12. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-1457
13. Raffi F, Katlama C, Saag M, Wilkinson M, Chung J, Smiley L, Salgo M. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 2006; 42: 870-877
14. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, Stanzione M, David E, Brancaccio G, Fontana R, Perri F, Andriulli A, Rizzetto M. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44: 713-720
15. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-960
16. Ahmed SI, Mahmud MR, Khan NY, Naseemullah M, Hanif M. Pegylated interferon and ribavirin in HCV genotype 3 detectable patients after 12 weeks of conventional interferon - ribavirin treatment. Pakistan J Gastroenterol 2006; 20: 58-62
17. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832-836
18. Moucari R, Ripault MP, Oules V, Martinot-Peignoux M, Asselah T, Boyer N, EI Ray A, Cazals-Hatem D, Vidaud D, Valla D, Bourliere M, Marcellin P. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007; 46: 596-604
19. Mira JA, Valera-Bestard B, Arizcorreta-Yarza A, Gonzolez-Serrano M, Torre-Cisneros J, Santos I, Vergara S, Gutierrez-Valencia A, Giron-Gonzalez JA, Macias J, Lopez-Cortes LF, Pineda JA. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. Antivir Ther 2007; 12: 523-529
20. Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, Chiu CF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-559
21. Hamid S, Umar M, Alam A, Siddiqui A, Qureshi H, Butt J. PSG consensus statement on management of hepatitis C virus infection-2003. J Pak Med Assoc 2004; 54: 146-150
22. Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD) and ribavirin. Scand J Gastroenterol 2007; 42: 247-255